Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review

OBJECTIVES: This study was aimed to systematically review published economic studies to determine whether dapagliflozin, a sodium-glucose co-transporter inhibitor, plus standard care therapy (SCT) is cost-effective in heart failure with reduced ejection fraction (HFrEF). METHOD: We searched relevant...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohammadnezhad, Ghader, Azadmehr, Behniya, Mirheidari, Mehdi, Yousefi, Nazila
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714165/
https://www.ncbi.nlm.nih.gov/pubmed/36457018
http://dx.doi.org/10.1186/s12962-022-00396-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9714165/
https://www.ncbi.nlm.nih.gov/pubmed/36457018
http://dx.doi.org/10.1186/s12962-022-00396-7

Ejemplares similares